CheckMyRecalls

10,013 recalls · updated 20 Nov 2026

Lupin Pharmaceuticals Inc. recalls Liraglutide Injection

Read the official FDA notice

Published
27 May 2026
Units affected
217,621 pen injectors
Agency
FDA
Country
United States

The hazard

Presence of particulate matter: a white thread-like structure in the cartridge

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.

Brand / company
Lupin Pharmaceuticals Inc.
Codes / lots
Lots: a) WB00097, WB00094, WB00088, Expires: Jul. 2027; WB00103, Expires: Oct. 2027; WC00016, Expires: Dec. 2027; b) WB00098, WB00092, WB00093, Expires: Jul. 2027; WB00104, WB00106, WB00105, Expires: Oct. 2027.
Distribution
Nationwide within U.S
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 27 May 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.